Company intelligence / Profile preview

F4 Pharma

Ownership: Private
Development stage: Phase 2

Overview

F4 Pharma’s lead product FX06 has demonstrated efficacy in improving vascular integrity by reducing capillary leakage and inflammation. It has shown promise in animal models and clinical trials for conditions such as ARDS and systemic capillary leak syndrome. As of June 2023, five Phase II programs were ongoing with over two hundred patients enrolled. The compound was originally discovered at the Medical University of Vienna.

Therapeutic areas: PulmonologyCardiovascularRare DiseasesInfectious Diseases
Modalities: Peptides (notably FX06)
Industry: Biotech

Drug pipeline

1 asset

FX06

Phase 2

Indications: COVID-19, ARDS, Capillary leak syndrome, Sepsis, Hemorrhagic fever

Partnerships

Collaboration with Nagoya University Hospital and Nagoya City University Hospital in Japan for clinical research.

Beyond the preview

Go deeper on F4 Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F4 Pharma.

Explore the full profile